Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Emplicure.

    Client Virtual Booth

    EMPLICURE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Emplicure
    Sweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Virdings allé 32B 754 50 Uppsala
    Telephone
    Telephone
    +46 708 59 07 35
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://emplicure.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokineti...

    Details:

    Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.


    Lead Product(s): Buprenorphine

    Therapeutic Area: Neurology Product Name: Empli03

    Highest Development Status: Phase IProduct Type: Small molecule

    Recipient: Quotient Sciences

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership November 29, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Emplicure AB Announce Completion of Phase I PK Study for EMPLI03 with Quotient Sciences

    Details:

    EMPLI03, intended for the treatment of moderate to severe pain. 12 healthy subjects were given a single dose of an oral buccal tablet and blood samples were collected for analysis of Buprenorphine.


    Lead Product(s): Buprenorphine

    Therapeutic Area: Neurology Product Name: EMPLI03

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Quotient Sciences

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 27, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search